Immunotherapy in Melanoma | Specialty

The OncLive Immunotherapy in Melanoma condition center page is a comprehensive resource for clinical news and expert insights on available and investigational immunotherapies in melanoma and other skin cancers. This page features news articles, interviews in written and video format, and podcasts that focus on updates with checkpoint inhibitors and the ongoing research with this type of treatment.

Dr. Atkins on Adjuvant Ipilimumab in Melanoma

April 7th 2016

Michael B. Atkins, MD, deputy director, Georgetown-Lombardi Comprehensive Cancer Center, professor of Oncology and Medicine, Georgetown University School of Medicine, discusses the adjuvant use of ipilimumab (Yervoy) in patients with melanoma.

Immunotherapy Combinations Coming to the Forefront in Melanoma

April 7th 2016

PD-1/PD-L1 should be the backbone of melanoma treatment for many patients, says Jason Luke, MD, an assistant professor of Medicine at the University of Chicago Medicine.

Expert Explains Key Considerations With Immunotherapy in Melanoma

April 5th 2016

Tara C. Mitchell, MD, discusses what oncologists need to know about using immunotherapies in melanomaÃ¢â‚¬â€

FDA Approvals, New Biopsy Techniques Advance Head and Neck Melanoma Care

April 4th 2016

Carol Rossier Bradford, MD, discusses the treatment and surgical outlook for head and neck melanoma, as well as other subtypes of the disease.

PI3K/AKT Pathway Potential Target for Treating Brain Mets in Melanoma

April 4th 2016

Michael Davies, MD, discusses the biggest challenges in treating brain metastases, what is known about the connection to the PI3K/AKT pathway, and what his future plans are for research in this area.

CHMP Recommends Approval of Nivolumab/Ipilimumab Combo for Melanoma

April 1st 2016

The combination of ipilimumab and nivolumab has received a positive recommendation from the CHMP, which suggests that the treatment is likely to gain European approval for patients with advanced melanoma.

Dr. Postow on Nivolumab Combined With Ipilimumab in Melanoma

March 31st 2016

Michael Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) for the treatment of patients with melanoma.

TILs Advancing as Melanoma Immunotherapy Option

March 31st 2016

After nearly 30 years of research, tumor-infiltrating lymphocyte technology is being investigated as a means of producing personalized immunotherapy for patients with metastatic melanoma in a small clinical trial that may help open the door for broader application in other solid tumor types.

The New Front Line in Melanoma: Immunotherapy or Targeted Agents?

March 16th 2016

The bounty of choices is good news for patients with melanoma, several key questions have emerged: Should immunotherapy or targeted agents be the first-line choice for metastatic melanoma?

OPTiM Follow-up Shows Improved CR Rate With T-VEC in Melanoma

March 7th 2016

Robert Andtbacka, MD, explains the goals of the retrospective analysis of the OPTiM study, the significance of its results, and the future for T-VEC in melanoma.

Expert Shares Challenges, Considerations When Using Immunotherapies in Melanoma

March 7th 2016

Michael Postow, MD, discusses the benefits and challenges of combination regimens versus single-agent regimens, the possibility of targeted agents with immunotherapies, and the management of toxicities with immunotherapies.

Will Immunotherapy or Targeted Therapy Take the Lead in Melanoma?

March 5th 2016

Michael Atkins, MD, discusses his views on the potential of immunotherapy versus targeted therapy in melanoma, what research has shown so far, and what could be on horizon for both classes of drugs going forward.

Dr. Tara C. Gangadhar on Atypical Responses with Immunotherapies in Melanoma

March 3rd 2016

Tara C. Mitchell, MD, assistant professor of Medicine at the Hospital of the University of Pennsylvania, Perelman School of Medicine, discusses atypical responses with immunotherapies in melanoma.

Beyond BRAF: Emerging Agents Aim at Other Melanoma Targets

March 2nd 2016

Jason Luke, MD, discusses how molecular subtyping has expanded targeted therapy approaches beyond BRAF inhibition, current trials investigating emerging targeted agents, and what can be expected in this space going forward.

Dr. Randal Weber on Future Treatment Approaches for Patients With Melanoma

March 1st 2016

Randal S. Weber, MD, FACS, professor, department chair, John Brooks Williams and Elizabeth Williams Distinguished University Chair in Cancer Medicine, Department of Head and Neck Surgery, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses future treatment approaches for patients with melanoma.

Weber Compares BRAF/MEK, Immunotherapy Combos in Melanoma

March 1st 2016

Jeffrey S. Weber, MD, PhD, discusses recent long-term follow-up data of dabrafenib and trametinib in melanoma that may shed some light on sequencing questions for BRAF-mutated patients.

Novel Checkpoints Offer Hope After Standard Melanoma Immunotherapies Fail

February 29th 2016

Omid Hamid, MD, discusses promising agents and combinations that offer hope to patients with melanoma for whom standard checkpoint agents and/or targeted therapies are not an option.

Dr. Andtbacka on Ongoing Trials With Oncolytic Immunotherapies in Melanoma

February 9th 2016

Robert Andtbacka, MD, associate professor, Division of Surgical Oncology, Department of Surgery, University of Utah School of Medicine, discusses ongoing clinical trials investigating oncolytic immunotherapies as a treatment for melanoma.

Melanoma Brings Immunotherapy to the Forefront, But Challenges Remain

February 9th 2016

Jeffrey S. Weber, MD, PhD, discusses the role that melanoma specialists can play in educating other oncologists, immunotherapy use for BRAF-mutated patients with melanoma, and how the use of chemotherapy may evolve as immunotherapies take the forefront.

Immunotherapy Shows Potential in Rare Melanoma Subtype

February 9th 2016

Richard Joseph, MD, discusses the challenges of treating mucosal melanoma and what oncologists need to know prior to using immunotherapies for the treatment of both mucosal and cutaneous melanomas.